Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

IL1-TRAP, Rilonacept, in Systemic Sclerosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2015 by Boston University
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Robert Lafyatis, Boston University Identifier:
First received: February 21, 2012
Last updated: January 26, 2015
Last verified: January 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)